Kerry M Sheets1, Mohamed G Atta, Derek M Fine, Katie Zook, Allison M Mcfall, Michelle M Estrella, George J Schwartz, Gregory M Lucas. 1. *Internal Medicine Residency Training Program, Johns Hopkins Bayview Medical Center, Baltimore, MD; †Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; ‡Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; §Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD; ‖Kidney Health Research Collaborative, San Francisco VA Medical Center and University of California, San Francisco, CA; and ¶Department of Pediatrics, University of Rochester Medical Center, Rochester, NY.
Abstract
BACKGROUND: Proximal tubular dysfunction (PTD) is common in HIV-positive persons and has been associated with tenofovir disoproxil fumarate (TDF). However, few studies have assessed the natural history PTD in HIV-positive and -negative individuals, or the association of PTD with the subsequent trajectory of directly measured glomerular filtration rate (mGFR). METHODS: We followed 192 HIV-positive and 100 HIV-negative, nondiabetic participants for 3 years. We measured 3 PTD markers (normoglycemic glycosuria, fractional excretion of phosphorus, and tubular proteinuria) and mGFR (by iohexol disappearance from serum) annually. We used univariate and multivariate generalized estimating equation logistic regression to identify factors associated with PTD across all visits and linear mixed effects models to assess the association between baseline PTD and mGFR slope. RESULTS: Compared with HIV-negative participants, HIV-positive persons that were not taking antiretroviral therapy were at increased risk of PTD (adjusted odds ratio 3.33; 95% confidence interval: 1.65 to 6.71), whereas those taking a TDF-based or a TDF-sparing regimen were not at significantly increased risk of PTD. Among HIV-positive participants, uncontrolled viremia was a strong correlate of PTD. Forty-nine of 55 (89%) participants with PTD at baseline had at least 1 subsequent visit without PTD. There was no association between baseline PTD and rate of decline in mGFR over time. CONCLUSIONS: Poorly controlled HIV may be a stronger risk factor for PTD than TDF use. The individual-level variability of the PTD markers over time was high, potentially limiting their usefulness for routine screening in unselected patients. Baseline PTD was not associated with subsequent mGFR slope.
BACKGROUND: Proximal tubular dysfunction (PTD) is common in HIV-positive persons and has been associated with tenofovir disoproxil fumarate (TDF). However, few studies have assessed the natural history PTD in HIV-positive and -negative individuals, or the association of PTD with the subsequent trajectory of directly measured glomerular filtration rate (mGFR). METHODS: We followed 192 HIV-positive and 100 HIV-negative, nondiabeticparticipants for 3 years. We measured 3 PTD markers (normoglycemic glycosuria, fractional excretion of phosphorus, and tubular proteinuria) and mGFR (by iohexol disappearance from serum) annually. We used univariate and multivariate generalized estimating equation logistic regression to identify factors associated with PTD across all visits and linear mixed effects models to assess the association between baseline PTD and mGFR slope. RESULTS: Compared with HIV-negative participants, HIV-positive persons that were not taking antiretroviral therapy were at increased risk of PTD (adjusted odds ratio 3.33; 95% confidence interval: 1.65 to 6.71), whereas those taking a TDF-based or a TDF-sparing regimen were not at significantly increased risk of PTD. Among HIV-positive participants, uncontrolled viremia was a strong correlate of PTD. Forty-nine of 55 (89%) participants with PTD at baseline had at least 1 subsequent visit without PTD. There was no association between baseline PTD and rate of decline in mGFR over time. CONCLUSIONS: Poorly controlled HIV may be a stronger risk factor for PTD than TDF use. The individual-level variability of the PTD markers over time was high, potentially limiting their usefulness for routine screening in unselected patients. Baseline PTD was not associated with subsequent mGFR slope.
Authors: Paul E Sax; David Wohl; Michael T Yin; Frank Post; Edwin DeJesus; Michael Saag; Anton Pozniak; Melanie Thompson; Daniel Podzamczer; Jean Michel Molina; Shinichi Oka; Ellen Koenig; Benoit Trottier; Jaime Andrade-Villanueva; Gordon Crofoot; Joseph M Custodio; Andrew Plummer; Lijie Zhong; Huyen Cao; Hal Martin; Christian Callebaut; Andrew K Cheng; Marshall W Fordyce; Scott McCallister Journal: Lancet Date: 2015-04-15 Impact factor: 79.321
Authors: Leal C Herlitz; Sumit Mohan; Michael B Stokes; Jai Radhakrishnan; Vivette D D'Agati; Glen S Markowitz Journal: Kidney Int Date: 2010-09-01 Impact factor: 10.612
Authors: Andrew M Hall; Simon G Edwards; Marta Lapsley; John O Connolly; Kreesan Chetty; Stephen O'Farrell; Robert J Unwin; Ian G Williams Journal: Am J Kidney Dis Date: 2009-09-23 Impact factor: 8.860
Authors: Pablo Labarga; Pablo Barreiro; Luz Martin-Carbonero; Sonia Rodriguez-Novoa; Carmen Solera; Jose Medrano; Pablo Rivas; Marta Albalater; Francisco Blanco; Victoria Moreno; Eugenia Vispo; Vincent Soriano Journal: AIDS Date: 2009-03-27 Impact factor: 4.177
Authors: Joel E Gallant; Eric S Daar; François Raffi; Cynthia Brinson; Peter Ruane; Edwin DeJesus; Margaret Johnson; Nathan Clumeck; Olayemi Osiyemi; Doug Ward; Javier Morales-Ramirez; Mingjin Yan; Michael E Abram; Andrew Plummer; Andrew K Cheng; Martin S Rhee Journal: Lancet HIV Date: 2016-03-14 Impact factor: 12.767
Authors: X Q Le; D P Liu; J Chen; Z Y Gong; J N Xun; J R Wang; J J Sun; C Steinhart; L Liu; Y Z Shen; T K Qi; Z Y Wang; X Zhang; Y Tang; W Song; H Z Lu; R F Zhang Journal: HIV Med Date: 2021-06-10 Impact factor: 3.180